30 September 2023
Kirkland Represents KKR-backed Slayback Pharma in Sale to Azurity Pharmaceuticals
Advising firms
Deal team
15 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Neil Vohra Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Andrew Arons Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Jennifer Perkins Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Lisa Gunter | Kirkland & Ellis | Associate | corporate | Not stated |
| Sophie Frishberg | Kirkland & Ellis | Associate | corporate | Not stated |
| Gino Jacobazzi | Kirkland & Ellis | Associate | corporate | Not stated |
| Rich Cunningham | Kirkland & Ellis | Partner | antitrust & competition | Not stated |
| Samantha Morelli | Kirkland & Ellis | Partner | antitrust & competition | Not stated |
| Mike Beinus | Kirkland & Ellis | Partner | tax | Not stated |
| Vivek Ratnam | Kirkland & Ellis | Partner | tax | Not stated |
| Paul Rezvani | Kirkland & Ellis | Partner | debt finance | Not stated |
| Ashley Martin | Kirkland & Ellis | Associate | debt finance | Not stated |
| Negin Fatahi | Kirkland & Ellis | Associate | debt finance | Not stated |
| Daniel Lewis | Kirkland & Ellis | Partner | technology & IP transactions | Not stated |
| Amber Harezlak | Kirkland & Ellis | Partner | technology & IP transactions | Not stated |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Slayback Pharma LLCSell-side
- Counterparties
- Azurity Pharmaceuticals Inc (Buy-side)